{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T14:19:41Z","timestamp":1761488381168},"reference-count":72,"publisher":"Oxford University Press (OUP)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2010,2,1]]},"DOI":"10.2146\/ajhp080559","type":"journal-article","created":{"date-parts":[[2010,1,26]],"date-time":"2010-01-26T00:28:00Z","timestamp":1264465680000},"page":"193-205","source":"Crossref","is-referenced-by-count":8,"title":["Etravirine: A novel nonnucleoside reverse transcriptase inhibitor for managing human immunodeficiency virus infection"],"prefix":"10.1093","volume":"67","author":[{"given":"Raghda K.","family":"Elsayed","sequence":"first","affiliation":[{"name":"University of Mississippi Medical Center, Jackson, MS; at the time of writing, she was a student, College of Pharmacy, University of Louisiana at Monroe, Monroe"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David J.","family":"Caldwell","sequence":"additional","affiliation":[{"name":"Department of Clinical and Administrative Sciences, College of Pharmacy, University of Louisiana at Monroe"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","reference":[{"key":"key\n\t\t\t\t2019041104231905200_b1-0670193","unstructured":"Joint United Nations Programme on HIV\/AIDS and World Health Organization. 2007 AIDS epidemic update: global overview. www.unaids.org\/en (accessed 2008 Jul 20)."},{"key":"key\n\t\t\t\t2019041104231905200_b2-0670193","unstructured":"Centers for Disease Control and Prevention. HIV\/AIDS surveillance report, 2006. www.cdc.gov\/hiv\/topics\/surveillance\/resources\/reports (accessed 2009 Nov 17)."},{"key":"key\n\t\t\t\t2019041104231905200_b3-0670193","first-page":"287","article-title":"Fresh from the pipeline: etravirine","volume":"7","author":"Haubrich","year":"2008","journal-title":"Nat Rev"},{"key":"key\n\t\t\t\t2019041104231905200_b4-0670193","unstructured":"Department of Health and Human Services. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. www.aidsinfo.nih.gov\/ContentFiles\/AdultandAdolescentGL.pdf (accessed 2009 Feb 10)."},{"key":"key\n\t\t\t\t2019041104231905200_b5-0670193","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1001\/jama.300.5.555","article-title":"Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society\u2013USA panel","volume":"300","author":"Hammer","year":"2008","journal-title":"JAMA"},{"key":"key\n\t\t\t\t2019041104231905200_b6-0670193","unstructured":"BHIVA guidelines. BHIVA guidelines for the treatment of HIV-infected adults with antiretroviral therapy 2008: prepress version. www.bhiva.org\/cms1222226.asp (accessed 2008 Aug 1)."},{"key":"key\n\t\t\t\t2019041104231905200_b7-0670193","volume-title":"Rescriptor (delaviridine) package insert","year":"2006"},{"key":"key\n\t\t\t\t2019041104231905200_b8-0670193","author":"Sustiva (efavirenz) package insert","year":"2008"},{"key":"key\n\t\t\t\t2019041104231905200_b9-0670193","volume-title":"Viramune (nevirapine) package insert","year":"2008"},{"key":"key\n\t\t\t\t2019041104231905200_b10-0670193","volume-title":"Intelence (etravirine) package insert","year":"2008"},{"key":"key\n\t\t\t\t2019041104231905200_b11-0670193","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1056\/NEJMoa074609","article-title":"Class-sparing regimens for initial treatment of HIV-1 infection","volume":"358","author":"Riddler","year":"2008","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2019041104231905200_b12-0670193","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1097\/00002030-200109070-00011","article-title":"Comparison of initial combination anti-retroviral therapy with a single protease inhibitor, ritonavir and saquinavir, or efavirenz","volume":"15","author":"Lucas","year":"2001","journal-title":"AIDS"},{"key":"key\n\t\t\t\t2019041104231905200_b13-0670193","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1056\/NEJMoa030264","article-title":"Comparison of sequential three-drug regimens as initial therapy for HIV-1 infection","volume":"349","author":"Robbins","year":"2003","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2019041104231905200_b14-0670193","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1016\/S0140-6736(04)15997-7","article-title":"Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study","volume":"363","author":"Leth","year":"2004","journal-title":"Lancet"},{"key":"key\n\t\t\t\t2019041104231905200_b15-0670193","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1056\/NEJM199912163412501","article-title":"Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults","volume":"341","author":"Staszewski","year":"1999","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2019041104231905200_b16-0670193","unstructured":"Intelence (etravirine) receives marketing authorisation in the European Union for HIV combination therapy. www.tibotec.com\/news (accessed 2008 Sep 30)."},{"key":"key\n\t\t\t\t2019041104231905200_b17-0670193","first-page":"437","article-title":"TMC125, a novel next-generation non-nucleoside reverse transcriptase inhibitor active against reverse transcriptase inhibitor-resistant human immunodeficiency virus type 1","volume":"4","author":"Andries","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t2019041104231905200_b18-0670193","doi-asserted-by":"crossref","first-page":"12773","DOI":"10.1128\/JVI.79.20.12773-12782.2005","article-title":"TMC125 displays a high genetic barrier to the development of resistance: evidence from in vitro selection experiments","volume":"79","author":"Vingerhoets","year":"2005","journal-title":"J Virol"},{"key":"key\n\t\t\t\t2019041104231905200_b19-0670193","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1021\/jm040127p","article-title":"From 4,5,6,7- tetrahydro-5-methylimidazo[4,5,1-jk] (1,4)benzodiazepin-2(1H)-one (TIBO) to etravirine (TMC125): fifteen years of research on non-nucleoside inhibitors of HIV-1 reverse transcriptase","volume":"48","author":"De Corte","year":"2005","journal-title":"J Med Chem"},{"key":"key\n\t\t\t\t2019041104231905200_b20-0670193","unstructured":"National Library of Medicine: ChemID- plus Advanced. Etravirine. www.chem.sis.nlm.nih.gov\/chemidplus (accessed 2008 Jul 15)."},{"key":"key\n\t\t\t\t2019041104231905200_b21-0670193","doi-asserted-by":"crossref","first-page":"2550","DOI":"10.1021\/jm030558s","article-title":"Roles of conformational and positional adaptability in structure-based design of TMC125-R165335 (etravirine) and related non-nucleoside reverse transcriptase inhibitors that are highly potent and effective against wild-type and drug-resistant HIV-1 variants","volume":"47","author":"Das","year":"2004","journal-title":"J Med Chem"},{"key":"key\n\t\t\t\t2019041104231905200_b22-0670193","first-page":"1273","article-title":"Antiretroviral agents and treatment of HIV infection","volume-title":"Goodman and Gilman\u2019s the pharmacological basis of therapeutics","author":"Flexner","year":"2006","edition":"11th ed"},{"key":"key\n\t\t\t\t2019041104231905200_b23-0670193","doi-asserted-by":"crossref","first-page":"8005","DOI":"10.1074\/jbc.M608274200","article-title":"HIV-1 reverse transcriptase plus-strand initiation exhibits preferential sensitivity to non-nucleoside reverse transcriptase inhibitors in vitro","volume":"282","author":"Grobler","year":"2007","journal-title":"J Biol Chem"},{"key":"key\n\t\t\t\t2019041104231905200_b24-0670193","doi-asserted-by":"crossref","first-page":"1","DOI":"10.5688\/aj7005100","article-title":"The pharmacology of HIV drug resistance","volume":"70","author":"Zdanowicz","year":"2006","journal-title":"Am J Pharm Educ"},{"key":"key\n\t\t\t\t2019041104231905200_b25-0670193","doi-asserted-by":"crossref","first-page":"e119","DOI":"10.1371\/journal.ppat.0020119","article-title":"Potent nonnucleoside reverse transcriptase inhibitors target HIV-1 Gag-Pol","volume":"2","author":"Figueiredo","year":"2006","journal-title":"PLoS Pathog"},{"key":"key\n\t\t\t\t2019041104231905200_b26-0670193","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1097\/QAD.0b013e3282170ab1","article-title":"Pharmacokinetics and antiretroviral response to darunavir\/ritonavir and etravirine combination in patients with high-level viral resistance","volume":"21","author":"Boffito","year":"2007","journal-title":"AIDS"},{"key":"key\n\t\t\t\t2019041104231905200_b27-0670193","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1177\/135965350801300505","article-title":"Single- and multiple-dose pharmacokinetics of etravirine administered as two different formulations in HIV-1-infected patients","volume":"13","author":"Kakuda","year":"2008","journal-title":"Antivir Ther"},{"key":"key\n\t\t\t\t2019041104231905200_b28-0670193","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0140-6736(07)61048-4","article-title":"Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-2: 24-week results from a randomised, double-blind, placebo-controlled trial","volume":"370","author":"Lazzarin","year":"2007","journal-title":"Lancet"},{"key":"key\n\t\t\t\t2019041104231905200_b29-0670193","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0140-6736(07)61047-2","article-title":"Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomised, double-blind, placebo-controlled trial","volume":"370","author":"Madruga","year":"2007","journal-title":"Lancet"},{"key":"key\n\t\t\t\t2019041104231905200_b30-0670193","article-title":"Pharmacokinetics of etravirine (ETR; TMC125) are not affected by sex, age, race, use of enfuvirtide (ENF) or treatment duration in HIV-1-infected subjects","author":"Kakuda"},{"key":"key\n\t\t\t\t2019041104231905200_b31-0670193","article-title":"Pharmacokinetics and pharmacodynamics of the NNRTI TMC125 in treatment- experienced HIV-1-infected patients: pooled 24-week results of DUET-1 and DUET-2","author":"Kakuda"},{"issue":"suppl","key":"key\n\t\t\t\t2019041104231905200_b32-0670193","first-page":"S34","article-title":"Impact of baseline NNRTI mutations on the virological response to TMC125 (etravirine; ETR) in the DUET-1 and DUET-2 phase III clinical trials","volume":"12","author":"Vingerhoets","year":"2007","journal-title":"Antivir Ther"},{"key":"key\n\t\t\t\t2019041104231905200_b33-0670193","unstructured":"Vingerhoets J Peeters M Azijn H . An update of the list of NNRTI mutations associated with decreased virologic response to etravirine (ETR): multivariate analyses on the pooled DUET-1 and DUET-2 clinical trial data. www.hivdb.stanford.edu\/pages\/pdf\/ETR_poster_Vingerhoets_2008.pdf (accessed 2009 Oct 28)."},{"key":"key\n\t\t\t\t2019041104231905200_b34-0670193","first-page":"62","article-title":"Update of the drug resistance mutations in HIV-1: spring 2008","volume":"16","author":"Johnson","year":"2008","journal-title":"Top HIV Med"},{"key":"key\n\t\t\t\t2019041104231905200_b35-0670193","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1093\/jac\/dkn297","article-title":"Prevalence of etravirine-associated mutations in clinical samples with resistance to nevirapine and efavirenz","volume":"62","author":"Llibre","year":"2008","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t2019041104231905200_b36-0670193","article-title":"Combined darunavir (DRV) and etravirine (TMC125; ETR) resistance analysis of the pooled DUET trials: when can we spare the other new classes?","author":"Haubrich"},{"key":"key\n\t\t\t\t2019041104231905200_b37-0670193","article-title":"Determination of phenotypic clinical cutoffs for etravirine (ETR): pooled week 24 results of the DUET-1 and DUET-2 trials","author":"Peeters"},{"key":"key\n\t\t\t\t2019041104231905200_b38-0670193","article-title":"Development of vircoTYPE HIV-1 resistance analysis, including clinical cut-offs for TMC125, a new NNRTI","author":"Winters"},{"key":"key\n\t\t\t\t2019041104231905200_b39-0670193","doi-asserted-by":"crossref","first-page":"F49","DOI":"10.1097\/00002030-200312050-00001","article-title":"An open-label assessment of TMC 125\u2014a new, next-generation NNRTI, for 7 days in HIV-1 infected individuals with NNRTI resistance","volume":"17","author":"Gazzard","year":"2003","journal-title":"AIDS"},{"key":"key\n\t\t\t\t2019041104231905200_b40-0670193","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.1097\/00002030-200311210-00011","article-title":"A randomized, double-blind, placebo-controlled trial of TMC125 as 7-day monotherapy in antiretroviral naive, HIV-1 infected subjects","volume":"17","author":"Gruzdev","year":"2003","journal-title":"AIDS"},{"key":"key\n\t\t\t\t2019041104231905200_b41-0670193","doi-asserted-by":"crossref","first-page":"F1","DOI":"10.1097\/QAD.0b013e32805e8776","article-title":"Efficacy and safety of etravirine (TMC125) in patients with highly resistant HIV-1: primary 24-week analysis","volume":"21","author":"TMC125-C223 Writing Group","year":"2007","journal-title":"AIDS"},{"key":"key\n\t\t\t\t2019041104231905200_b42-0670193","article-title":"Efficacy and safety results at 48 weeks with the novel NNRTI, TMC125, and impact of baseline resistance on the virologic response in study TMC125-C223","author":"Cohen"},{"key":"key\n\t\t\t\t2019041104231905200_b43-0670193","article-title":"Impact of NNRTI and NRTI resistance on the response to the regimen of TMC125 plus two NRTIs in study TMC125-C227","author":"Woodfall"},{"key":"key\n\t\t\t\t2019041104231905200_b44-0670193","unstructured":"Levin J . Conference report: impact of NNRTI and NRTI resistance on the response to the regimen of TMC125 plus two NRTIs in study TMC125-C227. www.natap.org\/2006\/Glasgow\/Glasgow_09.htm (accessed 2008 Aug 2)."},{"key":"key\n\t\t\t\t2019041104231905200_b45-0670193","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1086\/630210","article-title":"High rate of virologic suppression with raltegravir plus etravirine and darunavir\/ritonavir in patients infected with multidrug-resistant HIV: results of the ANRS 139 TRIO trial","volume":"49","author":"Yazdanpanah","year":"2009","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t2019041104231905200_b46-0670193","article-title":"Pooled 24-week results of DUET-1 and DUET-2: efficacy of TMC125 (etravirine; ETR) in treatment-experienced HIV-1-infected patients","author":"Katlama"},{"key":"key\n\t\t\t\t2019041104231905200_b47-0670193","first-page":"105","article-title":"Etravirine: a non-nucleoside reverse transcriptase inhibitor for the treatment of resistant HIV-1 infection","volume":"43","author":"Kehr","year":"2008","journal-title":"Formulary"},{"key":"key\n\t\t\t\t2019041104231905200_b48-0670193","article-title":"DUET-1: week 48 results of a phase III randomized double-blind trial to evaluate the efficacy and safety of TMC125 vs. placebo in 612 treatment-experienced HIV-1-infected patients","author":"Haubrich"},{"key":"key\n\t\t\t\t2019041104231905200_b49-0670193","article-title":"DUET-2: week 48 results of a phase III randomized double-blind trial to evaluate the efficacy and safety of TMC125 vs. placebo in 591 treatment-experienced HIV-1-infected patients","author":"Johnson"},{"key":"key\n\t\t\t\t2019041104231905200_b50-0670193","article-title":"Pooled 48-week analysis of DUET-1 and DUET-2: durable efficacy and safety results of etravirine (ETR; TMC125) in treatment-experienced HIV-infected patients","author":"Trottier"},{"key":"key\n\t\t\t\t2019041104231905200_b51-0670193","article-title":"Nucleoside-associated mutations cause hypersusceptibility to etravirine (ETR)","author":"Picchio"},{"key":"key\n\t\t\t\t2019041104231905200_b52-0670193","doi-asserted-by":"crossref","article-title":"A 48-week pooled analysis of DUET-1 and DUET-2: the impact of baseline characteristics on virological response to etravirine (TMC125; ETR)","author":"Cahn","DOI":"10.2217\/hiv.10.41"},{"key":"key\n\t\t\t\t2019041104231905200_b53-0670193","article-title":"The impact of background regimen on virologic response to etravirine: pooled 48-week analysis of DUET-1 and DUET-2","author":"Perri"},{"key":"key\n\t\t\t\t2019041104231905200_b54-0670193","article-title":"Impact of TMC125, a next-generation NNRTI, on clinical outcomes (AIDS-defining illnesses and deaths): 24-week findings from a planned pooled analysis of the DUET studies","author":"Gatell"},{"key":"key\n\t\t\t\t2019041104231905200_b55-0670193","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0140-6736(07)61022-8","article-title":"No patient left behind\u2014better treatments for resistant HIV infection","volume":"370","author":"Hirschel","year":"2007","journal-title":"Lancet"},{"key":"key\n\t\t\t\t2019041104231905200_b56-0670193","article-title":"Impact of etravirine on hospitalizations and hospital-related costs: 48-week findings from pooled DUET trials","author":"Gebo"},{"key":"key\n\t\t\t\t2019041104231905200_b57-0670193","article-title":"Efficacy, safety, and tolerability of etravirine with and without darunavir and\/or raltegravir in treatment-experienced patients: preliminary analysis of TMC125-C214 Early Access Program (EAP) in the US","author":"Towner"},{"key":"key\n\t\t\t\t2019041104231905200_b58-0670193","article-title":"Etravirine has no effect on fetal development in rats and rabbits","author":"Raoof"},{"key":"key\n\t\t\t\t2019041104231905200_b59-0670193","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1086\/591705","article-title":"Safety, tolerability, and preliminary efficacy of 48 weeks of etravirine therapy in a phase IIb dose-ranging study involving treatment-experienced patients with HIV-1 infection","volume":"47","author":"Montaner","year":"2008","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t2019041104231905200_b60-0670193","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1345\/aph.1K681","article-title":"Etravirine has no effect on QT and corrected QT interval in HIV-negative volunteers","volume":"42","author":"Peeters","year":"2008","journal-title":"Ann Pharmacother"},{"key":"key\n\t\t\t\t2019041104231905200_b61-0670193","article-title":"Incidence and severity of nervous system and psychiatric events are similar with etravirine versus placebo: pooled 48-week data from the phase III DUET studies","author":"Katlama"},{"key":"key\n\t\t\t\t2019041104231905200_b62-0670193","unstructured":"Food and Drug Administration. Potential signals of serious risks\/new safety information identified by the Adverse Event Reporting System (AERS), January\u2013March 2008. www.fda.gov\/Cder\/aers\/potential_signals\/potential_signals_2008Q1.htm (accessed 2009 Jan 12)."},{"key":"key\n\t\t\t\t2019041104231905200_b63-0670193","volume-title":"Data on file","year":"2008"},{"key":"key\n\t\t\t\t2019041104231905200_b64-0670193","article-title":"Pharmacokinetics and safety of adding TMC125 to stable regimens of saquinavir, lopinavir, ritonavir and NRTIs in HIV+ adults","author":"Harris"},{"key":"key\n\t\t\t\t2019041104231905200_b65-0670193","unstructured":"Benson CA Kaplan JE Masur H . Treating opportunistic infections among HIV-infected adults and adolescents. Recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association\/Infectious Diseases Society of America. http:\/\/aidsinfo.nih.gov\/contentfiles\/TreatmentofOI_AA.pdf (accessed 2009 Feb 11)."},{"key":"key\n\t\t\t\t2019041104231905200_b66-0670193","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1111\/j.1365-2125.2008.03214.x","article-title":"A pharmacokinetic study of etravirine (TMC125) co-administered with ranitidine and omeprazole in HIV-negative volunteers","volume":"66","author":"Sch\u00f6ller-Gy\u00fcre","year":"2008","journal-title":"Br J Clin Pharmacol"},{"key":"key\n\t\t\t\t2019041104231905200_b67-0670193","article-title":"No clinically relevant effect of etravirine (ETR; TMC125) on digoxin pharmacokinetics in HIV-negative volunteers","author":"Sch\u00f6ller-Gy\u00fcre"},{"key":"key\n\t\t\t\t2019041104231905200_b68-0670193","unstructured":"ClinicalTrials.gov. TMC125-TiDP35-C213: safety and antiviral activity of etravirine (TMC125) in treatment-experienced, HIV infected children and adolescents. www.clinicaltrials.gov\/ct2\/results?term=etravirine (accessed 2008 Oct 1)."},{"key":"key\n\t\t\t\t2019041104231905200_b69-0670193","article-title":"Pharmacokinetics of the next-generation NNRTI etravirine (ETR; TMC125) in HIV-infected children between 6 and 17 years, inclusive","author":"Kakuda"},{"key":"key\n\t\t\t\t2019041104231905200_b70-0670193","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1111\/j.1468-1293.2008.00644.x","article-title":"Impact of reverse transcriptase resistance on the efficacy of TMC125 (etravirine) with two nucleoside reverse transcriptase inhibitors in protease inhibitor-na\u00efve, nonnucleoside reverse transcriptase inhibitor-experienced patients: study TMC125-C227","volume":"9","author":"Ruxrungtham","year":"2008","journal-title":"HIV Med"},{"key":"key\n\t\t\t\t2019041104231905200_b71-0670193","unstructured":"ClinicalTrials.gov. Optimizing treatment for treatment-experienced, HIV-infected people. www.clinicaltrials.gov\/ct2\/results?term=etravirine (accessed 2008 Oct 1)."},{"key":"key\n\t\t\t\t2019041104231905200_b72-0670193","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1089\/apc.2007.0215","article-title":"Successful rescue therapy with raltegravir (MK-0518) and etravirine (TMC125) in an HIV-infected patient failing all four classes of antiretroviral drugs","volume":"22","author":"Di Biagio","year":"2008","journal-title":"AIDS Patient Care STDS"}],"container-title":["American Journal of Health-System Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ajhp\/article-pdf\/67\/3\/193\/28343390\/ajhp0193.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,23]],"date-time":"2024-03-23T03:55:03Z","timestamp":1711166103000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajhp\/article\/67\/3\/193\/5129956"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,2,1]]},"references-count":72,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2010,2,1]]}},"URL":"https:\/\/doi.org\/10.2146\/ajhp080559","relation":{},"ISSN":["1079-2082","1535-2900"],"issn-type":[{"value":"1079-2082","type":"print"},{"value":"1535-2900","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2010,2,1]]},"published":{"date-parts":[[2010,2,1]]}}}